Elranatamab-bcmm is a bispecific T-cell engager (BiTE) monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA), promoting the recruitment and activation of T cells to effectively eliminate malignant myeloma cells. It is FDA-approved for the treatment of adults with relapsed or refractory multiple myeloma. MW: 145.44 KD.

Sonelokimab is a humanized trivalent nanobody consisting of monovalent camelid-derived nanobodies that target human interleukin (IL)-17A, IL-17F, and human serum albumin. It exhibits clinical efficacy and dose-dependent modulation of psoriasis-associated genes in patients with plaque-type psoriasis. MW: 40.93 KD.

Duligotuzumab is a dual-action humanized IgG1 antibody that blocks ligand binding to the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). By inhibiting these interactions, it disrupts signalling from all ligand-dependent HER dimers and induces antibody-dependent cell-mediated cytotoxicity. It exhibits enhanced efficacy in EGFR inhibitor-resistant SCCHN and NSCLC models, with […]

Epcoritamab is a bispecific IgG1 antibody that targets CD3 and CD20, exhibiting strong T-cell-mediated cytotoxic activity against CD20+ malignant B cells. It is used in the treatment of adults in relapsed or refractory (R/R) large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma after ≥2 lines of systemic treatment. MW: 145.26 […]

Pm8002 is a bispecific antibody targeting both PD-L1 and VEGF-A, with potential immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities. It demonstrates promising antitumor effects in patients with previously treated platinum-resistant recurrent ovarian cancer (PROC) or cervical cancer, as well as in those with advanced solid tumors. MW : 172.48 KD.

Erfonrilimab is a humanized bispecific monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. It is used to treat solid tumors and exhibits promising efficacy in advanced non-small cell lung cancer (NSCLC) patients who had experienced failure or intolerance to […]

Lutikizumab is a humanized dual-variable domain (DVD) immunoglobulin G1 kappa (IgG1κ) that targets the inflammatory cytokines human interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β), exhibiting anti-inflammatory properties. It shows potential for treating knee osteoarthritis in patients with synovitis. MW: 196.82 KD.

Cadonilimab is a humanized tetravalent bispecific IgG1 antibody targeting human PD-1 and CTLA-4 with potential immune checkpoint inhibitory and antineoplastic activities. It has the potential to treat recurrent or metastatic cervical cancer. MW : 198.64 KD.

Tibulizumab (LY3090106) is a tetravalent bispecific antibody which potently inhibits both B cell activating factor (BAFF), also known as CD257 and interleukin-17A (IL-17). It is used for the treatment of autoimmune diseases. MW: 201.44 KD.

Amivantamab is a fully human bispecific antibody that targets both epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET). It exhibits immune anticancer activity in non-small cell lung cancer (NSCLC). MW :145.88 KD.